After the draft E9(R1) Addendum on estimands and sensitivity analysis in clinical trials was first introduced, one of the most frequently asked questions was whether the proposed framework was applicable to Oncology clinical trials and time-to-event endpoints. This webinar expands on how the estimand framework can help improve the way in which clinical trials are designed and planned, and how primary analyses and sensitivity analyses are appropriately conducted with an emphasis on the therapeutic area of Oncology and time-to event endpoints.
The webinar host is Kristina Bondareva, the Head of Biostatistics at OCT Clinical.
Learn more about OCT Clinical's biometrics services here: https://oct-clinicaltrials.com/services/biostatistics
